Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial
News
Trodelvy (sacituzumab govitecan), compared with standard chemotherapy, significantly prolonged overall survival and improved the overall response rate of patients with metastatic triple-negative breast cancer (mTNBC) who had at least two prior ... Read more